Details of the Drug

General Information of Drug (ID: DMZW9HA)

Drug Name

Olsalazine

Synonyms

Azodisal; Dipentum; Olsalazine sodium; Di-mesalazine

Indication

Disease Entry	ICD 11	Status	REF
Ulcerative colitis	DD71	Approved	[1]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

302.24

Topological Polar Surface Area (xlogp)

3.1

Rotatable Bond Count (rotbonds)

4

Hydrogen Bond Donor Count (hbonddonor)

4

Hydrogen Bond Acceptor Count (hbondacc)

8

ADMET Property

Clearance: The drug present in the plasma can be removed from the body at the rate of 1.2 mL/min/kg [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 0.9 hours [2]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 55.25308 micromolar/kg/day [3]
Unbound Fraction: The unbound fraction of drug in plasma is 0.01% [2]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.07 L/kg [2]

Chemical Identifiers

Formula: C14H10N2O6
IUPAC Name: 5-[(3-carboxy-4-hydroxyphenyl)diazenyl]-2-hydroxybenzoic acid
Canonical SMILES: C1=CC(=C(C=C1N=NC2=CC(=C(C=C2)O)C(=O)O)C(=O)O)O
InChI: InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)
InChIKey: QQBDLJCYGRGAKP-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 22419
ChEBI ID: CHEBI:7770
CAS Number: 15722-48-2
DrugBank ID: DB01250
TTD ID: D00KRE
ACDINA ID: D00487

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Oxidoreductase unspecific (OR)	TTPZ7AG	NOUNIPROTAC	Modulator	[4], [5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Olsalazine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Decreased renal excretion of Olsalazine caused by Remdesivir mediated nephrotoxicity.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[7]
Inotersen	DMJ93CT	Major	Increased risk of nephrotoxicity by the combination of Olsalazine and Inotersen.	Amyloidosis [5D00]	[8]
Iodipamide	DMXIQYS	Major	Increased risk of nephrotoxicity by the combination of Olsalazine and Iodipamide.	Cholelithiasis [DC11]	[9]
177Lu-DOTATATE	DMT8GVU	Moderate	Increased risk of nephrotoxicity by the combination of Olsalazine and 177Lu-DOTATATE.	Hepatitis virus infection [1E50-1E51]	[10]
Givosiran	DM5PFIJ	Moderate	Increased risk of nephrotoxicity by the combination of Olsalazine and Givosiran.	Inborn porphyrin/heme metabolism error [5C58]	[10]
Moxetumomab pasudotox	DMN63DZ	Moderate	Increased risk of nephrotoxicity by the combination of Olsalazine and Moxetumomab pasudotox.	Mature B-cell leukaemia [2A82]	[10]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Olsalazine and Exjade.	Mineral absorption/transport disorder [5C64]	[11]
Gallium nitrate	DMF9O6B	Moderate	Increased risk of nephrotoxicity by the combination of Olsalazine and Gallium nitrate.	Mineral excesses [5B91]	[10]
Temsirolimus	DMS104F	Moderate	Increased risk of nephrotoxicity by the combination of Olsalazine and Temsirolimus.	Renal cell carcinoma [2C90]	[10]
Salsalate	DM13P4C	Moderate	Increased risk of nephrotoxicity by the combination of Olsalazine and Salsalate.	Rheumatoid arthritis [FA20]	[10]
Telavancin	DM58VQX	Moderate	Increased risk of nephrotoxicity by the combination of Olsalazine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[10]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Olsalazine and Plazomicin.	Urinary tract infection [GC08]	[10]
-----------


⏷ Show the Full List of 12 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Caramel	E00350	61634	Colorant; Flavoring agent
Ferrosoferric oxide	E00231	14789	Colorant
Magnesium stearate	E00208	11177	lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Olsalazine 250 mg capsule	250 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	ClinicalTrials.gov (NCT00004288) Phase II Pilot Study of Olsalazine for Ankylosing Spondylitis. U.S. National Institutes of Health.
2	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
4	Reaction mechanism of azoreductases suggests convergent evolution with quinone oxidoreductases. Protein Cell. 2010 Aug;1(8):780-90.
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	Cerner Multum, Inc. "Australian Product Information.".
8	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
9	Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
10	Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
11	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.